Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Nuvalent Inc (NUVL) Price & Performance

KraneShares Hang Seng TECH Index ETFTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

KraneShares Hang Seng TECH Index ETF vs Nuvalent Inc — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.27, while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.

KTECNUVL
Sector
Sector/ThematicTechnology
52-Week High
$19.51$123.96
52-Week Low
$12.00$72.16
Market Cap
$9.81B
Enterprise Value
$8.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares Hang Seng TECH Index ETF

KTEC stock is trading at $13.28, up 2.23% today, showing positive momentum. The stock's technical picture indicates recent strength, though key financial ratios including P/E, P/S, and profitability metrics are currently unavailable for analysis. No recent earnings data or business developments are accessible to provide fundamental context.

Investment outlook remains unclear due to insufficient financial data. The primary opportunity lies in the stock's recent price appreciation, while risks include limited transparency on company fundamentals and the absence of analyst coverage or institutional positioning data to validate current valuation levels.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.

The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About KraneShares Hang Seng TECH Index ETF

KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.

Read more on KTEC

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL